Medicenna Reports 40% Response Rate for MDNA11 in Certain Gastrointestinal Cancers
Key Facts
Medicenna Therapeutics on November 17 announced a financial results and clinical program update, highlighting ABILITY-1 data that showed an objective response rate of 40% in a defined group of patients with gastrointestinal cancers. The company said the rate represented 8 responses among 20 patients evaluable for efficacy with MSI-H or MSS TMB-H tumors. The disease control rate in the same group was 80%, or 16 of 20 cases. The study is evaluating MDNA11 as a monotherapy and in combination with pembrolizumab. The company announced on November 4 that enrollment of 152 patients in the global study was complete.
The group’s figures take on significance in light of the treatments patients received before entering the study: the median number of prior lines of systemic therapy was 3, with a range of 1 to 10 lines, including adjuvant therapy. In addition, 65% had previously received immune checkpoint inhibitors. Of the recorded responses, the company confirmed 5 of the eight. The reported response rate includes unconfirmed cases and responses that are ongoing, according to the company’s statement. Median duration of response has not yet been reported, leaving the durability of the clinical effect unresolved in these data.
Results varied between the treatment arms in the gastrointestinal cancer group. MDNA11 monotherapy recorded an objective response rate of 36%, equivalent to 4 of 11 patients, and a disease control rate of 82%, or 9 of 11. The combination of MDNA11 and pembrolizumab recorded a response rate of 44%, or 4 of 9 patients, and a disease control rate of 78%, or 7 of 9. The comparison reflects results from two small groups within the study, with response and disease control rates differing between the treatments. The company did not provide a direct comparison in these figures establishing that either regimen was superior to the other.
Among patients who had not previously responded to checkpoint inhibitors, the objective response rate was 31%, or 4 of 13 patients. Monotherapy recorded 33%, or 3 responses among 9 patients, while the combination recorded 25%, or 1 response among 4 patients. The results put responses among patients who had previously resisted immunotherapy at the center of the clinical update, but they remain based on limited numbers in each group. The rates therefore differed between the two regimens in the resistant group, with responses recorded in both. The reported data did not include a statistical comparison between the treatment arms.
The company’s data also included measures of liver lesions in patients with MSI-H gastrointestinal cancer who received MDNA11 alone. Measurable target lesions declined in all 4 patients who could be evaluated, including all 8 measurable liver lesions. In the two groups of patients with stage IV melanoma, 90% had previously received treatment combining PD-1 and CTLA-4 inhibitors. The response rate was 30% in the secondary-resistance group, which received MDNA11 alone and included 10 patients, versus 38% in the primary-resistance group, which received the drug with pembrolizumab and included 8 patients. The group with MSS endometrial cancer resistant to immunotherapy also recorded a confirmed response rate of 28.6%, or 2 responses among 7 patients.
In August, Medicenna described earlier ABILITY-1 results as showing response rates in the 30% to 40% range in second- and third-line treatment settings or after resistance to checkpoint inhibitors. In that disclosure, it said enrollment remained on track for completion in the third quarter of 2026, before later announcing completion at 152 patients. On liquidity, the company’s previous results disclosed cash and cash equivalents of $5.7 million as of June 30, 2026, compared with $6.3 million as of March 31. It posted a quarterly net loss of $5.1 million for the three months ended June 30, compared with $4.9 million in the corresponding period of 2025. No verified figures for results for the quarter ended in September were available in the evidence, so these financial figures do not include an update for that quarter.
In a separate development in the company’s programs, Medicenna on November 16 announced phase 2 results for bizaxofusp in patients with recurrent, unresectable IDH-wildtype glioblastoma. Median overall survival was 13.7 months among the 19 patients treated at a dose of at least 180 micrograms, versus 6.2 months in a balanced external control group. The company reported a hazard ratio of 0.499 and a p-value of 0.013. For MDNA11, the company said in its August disclosure that it planned to present updated clinical results and discuss a potential development path with the U.S. Food and Drug Administration, including the possibility of an accelerated approval pathway. This was planned for an end-of-phase 1 meeting after the updated results were presented at a medical conference.